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To assess the efficacy of stem cells in the improvement of functional capacity and quality of life 
in the setting of nonischemic dilated cardiomyopathy.  
 
Design  
Systematic literature review 
 
Methods  
A literature search of PubMed was conducted utilizing the following search terms: “stem,” “cell,” 
“nonischemic,” and “cardiomyopathy.” The following limits were used: “2015-2018,” nonischemic 
cardiomyopathy, results of LVEF and 6MWT, randomized controlled trials, pilot studies, and 
sample size >22. 
 
Results  
Butler et al. found that within the itMSC group, 6MWD increased by an average of 27.40 m 
(95% CI 0.28–54.52; P=0.05), but it decreased by an average of 10.83 m (95% CI −38.66 to 
17.00, P=0.45) among control patients. The authors used exploratory analyses to examine 
changes from baseline after initial randomization and found significant increases in LVEF in the 
itMSC group (estimated mean difference was +2.31; P=0.02) with no significant changes in 
control group (+1.62; P=0.13.). Vrtovec et al. revealed improvement in LVEF and 6MWT in both 
single and repetitive dose groups (group A and group B), when comparing each group 
separately from baseline to 6 months (LVEF: +6.9±3.3% in group A, P=0.001 and +7.1±3.5% in 
group B, P=0.001; 6MWT: +87±21 m, P=0.03 and +92±25 m, P=0.02). Hare et al. found that at 
12 months post-treatment, LVEF increased in the allo-hMSC group by 8.0% (CI: 2.8% to 13.2%, 
p = 0.004) compared to baseline which was found to be statistically significant, but the LVEF 
increase of 5.4% in the auto-hMSC group was not statistically significant (CI: -1.4% to 12.1%; p 
= 0.116). At 12 months post-treatment, the 6MWT distance significantly increased in the allo-
hMSC treatment group by 37.0 meters (CI: 2.0m to 72.0m, p = 0.04) compared to baseline. At 
12 months post-treatment, the auto-hMSC treatment group 6MWT distance increased 7.3 







Stem cell therapy is shown to be safe, well-tolerated, and effective in improving functional 
capacity, quality of life, and short-term event survival in patients with nonischemic 
cardiomyopathy and, thus, is a promising alternative therapeutic option for patients with 
nonischemic cardiomyopathy and should be further explored in future studies.  
 
Abbreviations and Acronyms 
AMI - Acute myocardial infarction 
CHF - Chronic heart failure 
G-CSF - Granulocyte colony-stimulating factor  
HFrEF - Heart failure with reduced ejection fraction 
hMSC - Human mesenchymal stem cells 
ICD - Implantable cardioverter defibrillator 
LVEF - Left ventricular ejection fraction 
LVAD - Left ventricular assist device  
MSC - Mesenchymal stem cells 
NIDCM - Nonischemic dilated cardiomyopathy 
NYHA - New York Heart Association  
PAD - Peripheral artery disease 
6MWD- 6-minute walk distance 
6MWT - 6-minute walk test  
TE-SAE - Treatment-emergent serious adverse events 
TESI - Transendocardial stem cell injection 













Nonischemic dilated cardiomyopathy (NIDCM), often referred to as heart failure with 
reduced ejection fraction (HFrEF), is a disorder characterized by progressive degeneration and 
structural change of cardiac tissue leading to impaired contractile function of the heart. Since 
the only curative therapy for NIDCM at this time is heart transplantation, the primary goals of 
treatment are to improve cardiac function, reduce the symptoms of heart failure, and delay the 
need for heart transplantation for as long as possible.1 The burden of this disease is significant 
as NIDCM is currently the most common cause of heart failure leading to heart transplantation, 
accounting for 49.8% of all heart transplantations performed between January 2009 and June 
2016.2 Over the past decade, the number of donor hearts available per year has remained 
relatively stable, but the number of patients in advanced heart failure in need of transplantation 
has risen significantly.3 It is currently estimated that dilated cardiomyopathy is responsible for 
10,000 deaths and 46,000 hospitalizations each year in the USA.4 There are up to 50,000 
candidates for heart transplantation each year worldwide, but only 5,000 cardiac transplants are 
performed.5 Of those 10% who are lucky enough to receive a curative transplantation, 85% are 
expected to survive the first year post-transplant and mean survival time for all heart transplant 
recipients is estimated to be 11 years.6 The limited supply of donor hearts and the high pre- and 
post-heart transplant mortality rates is evidence of a great need for additional heart failure 
therapeutic and curative options. 
Stem cell-based therapies seem to be a promising new treatment option for NIDCM 
based on the results of several early phase clinical trials. Stem cells are a population of 
immature, undifferentiated cells, which have the potential to develop into a number of different 
specialized cell types. In the setting of NIDCM, it is hypothesized that stem cells have the 
potential to 1) aid in cardiac myocyte regeneration, 2) secrete factors that reduce the rate of 
apoptosis of endogenous cardiac myocytes, 3) promote angiogenesis, 4) activate endogenous 
cardiac stem cells to promote regeneration of new healthy tissue, and 5) induce the release of 
large amounts of anti-inflammatory factors which possibly have a significant role in myocyte 
repair.7 The goal of stem cell therapy in the treatment of NIDCM is to regain normal function of a 
damaged heart without the need for total heart transplantation.  
End point measurements of cardiac improvement after stem cell therapy evaluated in 
this paper include the 6-minute walk test distance (6MWT) and left ventricular ejection fraction 
(LVEF). The 6MWT and LVEF are indicators of functional capacity in patients with heart failure. 
This review will focus on recent evidence that stem cell therapy causes short term improvement 






An initial literature search of PubMed was conducted in September 2018 using the 
following search terms: “stem,” “cell,” “nonischemic,” and “cardiomyopathy.” The initial search 
yielded 83 results, 47 of which were excluded when the results were filtered by year: “2015-
2018.” The remaining 36 full-text articles were assessed for eligibility. Review articles, case 
reports, and animal trials were excluded. In addition, articles focusing on other disorders, 
without 6MWT as an outcome, and with sample size <22 were excluded. The three articles that 
remained were individually 
assessed using critical 
appraisal sheets and included 
in this analysis. A level of 
evidence was assigned to 
each study based on John 
Hopkins NURSING Evidence 
Level and Quality Guide.8 A 
summary of study criteria is 











Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy. Safety and 
Efficacy Results of a Phase II-A Randomized Trial. Butler et al.9 
 
Study Objective 
“To assess the safety and preliminary efficacy of intravenously administered ischemia-tolerant 








This was a crossover randomized phase II-a trial involving 22 patients with nonischemic 
cardiomyopathy with LVEF less than or equal to 40%, from across 4 sites in the United States, 
between June 2014 and April 2016. Table 2 outlines patient inclusion and exclusion criteria. 9 
Thirty-four patients were screened, 23 were randomized, and 22 were involved in the study. 
Eligible patients were blinded to treatment allocation and randomized 1:1 to either the control 
group, “placebo-itMSC,” (n=12) or the intervention group, “itMSC” (n=10). Of note, the control 
group data was defined as the data from the group which received the placebo treatment at time 
t=0 days, "placebo-itMSC." The intervention group data was defined as the data from the group 
which received the intervention treatment at time t=0 days, "itMSC," as well as the data from 
"placebo-itMSC" from t=90 days to t=180 days. Both groups were evaluated from baseline at 
t=0 days through t=90 days before crossover. At t=90 days, the "placebo-itMSC" group received 
interventional treatment and the "itMSC" group received placebo treatment. The “itMSC” group 
received placebo after the crossover from t=90 days through t=180 days, but was not included 
in the data analysis of the control 
group. The intervention treatment 
was an intravenous (IV) infusion of 
ischemia-tolerant allogenic 
mesenchymal stem cells (MSCs) 
dosed at 1.5 million cells/kg 
extracted from the bone marrow of a 
healthy volunteer and suspended in 
Lactated Ringer’s solution at a 
concentration of 1x106 cells/mL. The 
placebo was an IV infusion of 
Lactated Ringer’s solution at 1 
mL/kg.  At t=90 days post-initial treatment, each group crossed over; the "placebo-itMSC" group 
received intervention and the “itMSC” group received placebo, resulting in each patient 
receiving a total of 2 infusions during the study. The study timeline and flow of patients through 







Prior to treatment, demographic data, New York Heart Association (NYHA) class, vital 
signs, laboratory data (AST/ALT, BNP, Troponin, Sodium, Creatinine, Total Bilirubin, and 
Albumin), medical history, medications, and cardiac magnetic resonance imaging were collected 
as baseline data. Mean age of study participants was 47.3 years, over two-thirds were 
Caucasian, all but one patient had NYHA class II symptoms, and rate of comorbidities was low. 
Secondary efficacy endpoints included LVEF and 6MWT, among others. LVEF was measured 
at baseline, t=90 days, and t=180 days and 6MWT was measured at t=30 days and t=90 days 
after initial and second transfusion. The flow of treatment can be seen in Figure 2 above. At 
each time point, vital signs, 12-lead electrocardiograms, and laboratory tests were collected. 




Statistical analyses used a 2-sided 0.05 significance level. Continuous secondary efficacy 
endpoints were analyzed using linear regression and 95% confidence intervals. 
 
Study Results  
 At baseline, average LVEF was 31.6% ± 9.8%. At t=90 days, there was no significant 
difference between “placebo-itMSC” or “itMSC” groups as the estimated difference in LVEF was 
0.01% (95% CI -1.50-1.52; P=0.99). However, increases in LVEF in the itMSC group were 
shown “in ad hoc exploratory analyses 
that examined changes from baseline 
after initial randomization (ie, first 90 
days, pre crossover).” 9  The estimated 
mean difference was +2.31 (P=0.02). 
During this same time period, changes 
in those patients who were receiving 
placebo were not significant with a 
LVEF estimated mean difference of 
+1.62 (P=0.13). 
“Treatment with itMSCs 
resulted in statistically significant 
improvements in health status and 
functional capacity end points.” 9 
Compared to control, the change in 
six-minute walk distance (6MWD) from 
baseline to t=90 days after itMSC 
therapy was “significantly greater by 36.47 m (95% CI 5.98–66.97; P=0.02) or 15.9% [(See 
Figure 3)]. Specifically, within the “itMSC” group, 6MWD increased by an average of 27.40 m 
(95% CI 0.28–54.52; P=0.05), but it decreased by an average of 10.83 m (95% CI −38.66 to 
17.00, P=0.45) among control patients.” 9 
In summary, these results support clinical efficacy of IV stem cell infusion of ischemia-
tolerant allogeneic MSCs in the setting of nonischemic dilated cardiomyopathy since a 
statistically significant improvement from baseline was seen in the “itMSC” group in 6MWD and 
in ad hoc exploratory analyses of LVEF, indicating a significant improvement of health status 
and functional capacity in these patients as a result of this experimental therapy. If results of this 




considered as a less invasive therapeutic option to improve functional capacity as well as short-
term event-free survival in patients with NIDCM. 
 
Study Critique  
 Strengths of this study include the stringent inclusion and exclusion criteria as well as 
the rigorous definition of nonischemic cardiomyopathy defined using multiple clinical and 
objective parameters. Additionally, the use of multiple secondary efficacy endpoints helps to 
decrease the likelihood of chance findings when the results correspond. This study was also 
performed at 4 different sites in the US, limiting the chance of geographical elements. 
  This study is hampered by a small study size, though early phase studies primarily 
focusing on safety often have small sample sizes. The use of exploratory ad hoc analyses also 
provides an interesting challenge as significant results can be found, but still need prospective 
validation. The fact that this study was a crossover study can be both a strength and a 
hindrance. Crossover studies are helpful in that each participant acts as their own control, 
limiting between-subject variability. However, crossover studies are also a weakness as the 
researchers of this study “cannot definitively determine if any adverse event occurring>90 days 
after itMSC infusion within the itMSC–placebo group represents placebo effect, delayed 
consequence of cell therapy, or random chance.” An additional potential weakness in this study 
is that only MSCs grown under hypoxic conditions were used, due to previous studies reporting 
higher efficacy.10 The researchers did not test MSCs grown under normoxic conditions and, 
therefore, cannot conclude whether the ischemia-tolerant MSCs played a different role than that 
of normoxic MSCs. 
 
Level of Evidence: 1B  
 
Study #2 
Effects of Repetitive Transendocardial CD34+ Cell Transplantation in Patients With 
Nonischemic Dilated Cardiomyopathy. Vrtovec et al. 11 
Study Objective 
To investigate if repetitive administration of CD34+ cells is more effective than single 







This was a prospective randomized study involving 60 patients with nonischemic 
cardiomyopathy with LVEF less than or equal to 40%, “conducted at the Advanced Heart Failure 
and Transplantation Center at University Medical Center Ljubljana between January 2014 and 
September 2017 in collaboration with the Stanford Cardiovascular Institute.” 11 Table 3 outlines 
patient inclusion and exclusion criteria. Of the 89 patients screened, 66 patients were enrolled, 
and 6 were excluded due to inadequate response to granulocyte colony-stimulating factor (G-
CSF) stimulation, as the patient's own stem cells were used for the transplantation. The 
remaining 60 patients were randomly allocated in 1:1 ratio to receive either repetitive (group A) 
or single-dose (group B) CD34+ cell therapy. “During 1-year follow-up, there was 1 heart 
transplantation in group A versus 1 death and 1 heart transplantation in group B. Of the 6 
excluded patients, 1 patient died, and 1 underwent heart transplantation.” 11 The study timeline 





At baseline, demographic parameters, LVEF, exercise capacity, medications, 
comorbidities, and renal and liver function tests did not differ between groups. Mean age was 
55±10. Both groups received daily subcutaneous injections of G-CSF (10 μg/kg) for 5 days. 
CD34+ cells were collected via apheresis with Miltenyi cell separator “and the magnetic cell 
separator Isolex 300i was used for the immunomagnetic positive selection of the CD34+ cells.”11 
A standardized dose of 80 million CD34+ cells was used for transendocardial injection, guided 
by electronic mapping. “In group A, G-CSF stimulation, apheresis, electroanatomical mapping, 
and cell injections were repeated at 6 months.” Clinical evaluation, echocardiography, and 
6MWT were performed at baseline, 6 months, and 12 months. The primary end point of this 




was a secondary end point, among others. “Favorable clinical response to cell therapy was 
defined as the presence of increase in LVEF of at least 5% at 6 months after stem cell 
transplantation.” 11 
A blinded third party echocardiographer was recruited to analyze echocardiography data 
at the conclusion of the study and all of the data was averaged over 5 cycles. LVEF was 
estimated using the Simpson biplane method. In all patients, 6MWT was performed by a blinded 




At 1 year, there was no significant change in LVEF from 32.2±9.3% to 41.2±6.5% in 
group A and from 30.0±7.0% to 37.9±5.3% in group B, resulting in P=0.40. Additionally, there 
was no significant change in 6MWT between both groups at 1 year (from 320±92 to 434±71 m 
in group A and from 341±87 to 445±96 m in group B, P=0.65). However, both groups showed 
improvement in LVEF and 6MWT, when comparing each group separately, from baseline to 6 
months (LVEF: +6.9±3.3% in group A, P=0.001 and +7.1±3.5% in group B, P=0.001; 6MWT: 
+87±21 m, P=0.03 and +92±25 m, P=0.02). In contrast, there were no significant changes 
between 6 months and 1 year in LVEF or 6MWT (LVEF: +2.1±2.3% in group A, P=0.19 and 
+0.8±3.1% in group B, P=0.5; 6MWT: +27±11 m, P=0.2 and +12±18 m, P=0.42). These results 
are summarized below in Figure 5. 11 
In summary, these results do not support clinical superiority of repetitive 
transendocardial CD34+ cell transplantation over single dose transplantation at this time. These 
results do show statistically 
significant improvement in 
both LVEF and the 6MWT in 
each separate group from 
baseline to 6 months; 
however, there was no 
significant improvement in 
LVEF or the 6MWT from 6 
months to 1 year, 
suggesting a ceiling effect 
for cell therapy. If results of this clinical trial are replicated in a larger randomized control trial, 




therapeutic option to improve functional capacity as well as short-term event-free survival in 
patients with NIDCM. 
 
Study Critique 
Strengths of this study include the specific inclusion and exclusion criteria, with one of 
the inclusion criteria being NYHA class III symptoms. This is a strength because all individuals 
had comparable symptoms which ensured adequate and fair comparisons. These criteria also 
helped to create well-matched patient groups. In addition, included patients were followed in the 
researchers’ heart failure outpatient clinic for at least 3 months, which allowed for adequate 
optimization of medical therapy. 
This study is hampered by the heterogeneity within the definition of DCM. Multiple tests 
were performed on each patient prior to inclusion, but no biopsies were done to exclude 
secondary cardiomyopathies. There was also no placebo arm which limits the evaluation of the 
cell therapy effects. This study was also performed only at one center, with a small sample size, 
and outside of the United States, which potentially limits the ability to extrapolate data to larger 
or geographically different populations. The echocardiography data was analyzed by one 
echocardiographer, which could be interpreted as a strength or a weakness. Although it 
provides a sort of uniformity, multiple interpreters at multiple centers could provide valuable 
information if there was interobserver agreement. 
 
Level of Evidence: 1B 
 
Study #3  
Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for 
Nonischemic Dilated Cardiomyopathy. Hare et al. 12  
 
Study Objective 
To evaluate the safety and efficacy of autologous versus allogeneic bone marrow-










Study Design  
This was a randomized control trial in which 37 patients were recruited from the 
University of Miami Hospital between December 2011 and July 2015 and randomized 1:1 to 
receive either allo- or auto-hMSCs by transendocardial stem cell injection (TESI) in 10 left 
ventricular sites. End points 
evaluated included LVEF 
and 6MWT, among others. 
Table 4 outlines inclusion 
criteria for this study.   
Mean age of study 
participants was 55.8 years. 
29% of participants were 
female, 35% were Hispanic, 
and 50% had NYHA 
functional class II symptoms. Average baseline test results for LVEF and 6MWT were 26.5% ± 
9.64% and 422m ± 86.8m respectively.  
Of the 37 patients who were randomized into one of the two groups of this study, 3 did 
not receive the study injection of auto or allo-hMSCs: 1 withdrew consent before treatment, 1 
had an ICD placed prior to injection, 
and 1 died before treatment. The 
study timeline and flow of patients 
through the trial can be seen in 
Figure 6. 12  
All allo- and auto-hMSCs were 
manufactured at the University of 
Miami Interdisciplinary Stem Cell 
Institute. Auto-hMSCs were obtained 
from participants 4-6 weeks prior to 
cardiac catheterizations to allow 
ample time for sufficient ex vivo 
expansion prior to transendocardial 
injection of participant’s own cells.13 




the University of Miami Cell Production Facility from a pooled collection of donors. All allo-
hMSCs donors were male, Caucasian, with a mean age of 25.4 years. Allo-hMSCs were from 
11 men with a mean age of 58 years, and 6 women with a mean age of 55 years. Injections 
were then administered transendocardially during cardiac catheterization using the Biosense 
Webster MyoStar NOGA Catheter system.13 Injection sites for therapeutic administration were 
selected to distribute sites evenly throughout the accessible left ventricular myocardium and to 
prioritize safety of the transendocardial stem cell injection.  
Prior to treatment administration, baseline assessment of all patients was performed 
including chemistry and hematology laboratory tests, echocardiography, and CT scans or MRI 
imaging of the chest, abdomen, and pelvis. Following cardiac catheterization and TESI, patients 
were admitted to the hospital for a minimum of 2 days and were required to follow-up post-
treatment at 2 weeks and at 2, 3, 6, and 12 months for safety and efficacy evaluation. LVEF was 
evaluated at baseline and at 12 months. 6MWT results were evaluated at baseline, 6 months, 
and 12 months.  
The data analysis of this open-label study masked all parties involved in statistical 
analysis of results. All patients who received study injection were included in analysis. “All 
statistical tests were performed at alpha = 0.05 using 2-sided tests.” 12 
  
Study Results 
At 12 months post-treatment, the LVEF increased in the allo-hMSC group by 8.0% (CI: 
2.8% to 13.2%, p = 0.004) compared to baseline which was found to be statistically significant, 
but the LVEF increase of 5.4% in the auto-hMSC group was not statistically significant (CI: -
1.4% to 12.1%; p = 0.116). The statistically significant increase in the allo-hMSC group resulted 
in the post-treatment LVEF exceeding 40% in 46.7% of the patients in this group. The auto-
hMSC group post-treatment LVEF exceeded 40% in only 22.2% of patients in this group.  
At 12 months post-treatment, the 6MWT distance significantly increased in the allo-
hMSC treatment group by 37.0 meters (CI: 2.0m to 72.0m, p = 0.04) compared to baseline. At 
the same time point, the auto-hMSC treatment group 6MWT increase of 7.3 meters compared 
to baseline was not statistically significant (CI: -47.8m to 33.3m, p = 0.71). Figure 7 shows 




The primary safety endpoint measured in this study was the incidence of any treatment-
emergent serious adverse events (TE-SAEs) 
occurring within 30 days after treatment. There were 
no TE-SAEs observed in the first 30 days. Two 
deaths occurred post-injection in the auto-hMSC 
group, but both events were considered to be 
unrelated to the study treatment.  
In summary, these results support clinical 
efficacy of transendocardial stem cell infusion of 
allo-hMSCs in the setting of nonischemic dilated 
cardiomyopathy since a statistically significant 
improvement from baseline was seen in the allo-
hMSC group in LVEF and 6MWT, indicating that a 
significant improvement of functional capacity in 
these patients with NIDCM was achieved as a result 
of this experimental therapy. If results of this clinical 
trial are replicated in a larger randomized control 
trial, TESI of allo-hMSCs could be considered as a 
therapeutic option to improve functional capacity in 
patients with NIDCM.  
 
Study Critique 
Strengths of this study include the stringent inclusion and exclusion criteria used to 
select study participants, including all patients who received either treatment in the final data 
analysis, and consistency with location of stem cell collection and culture. This study is 
hampered by a very small sample size at a single hospital center, lack of a placebo group (by 
trial design), and loss of patients due to withdrawal of consent or loss to follow-up. The trial 
sample size was determined prospectively based on predicted rates of serious adverse events, 
and, although the sample size is too small to draw concrete conclusions regarding efficacy of 
therapy, the findings are valuable in designing future studies.  
It is important to note that the mean age of the stem cell donors in the allo-hMSC group 
was roughly one half of the mean age of the stem cell donors in the auto-hMSC group. This 
significant mean age difference between the stem cells used in the two treatment groups in this 




Implications of this difference between treatment groups include the possibility that study end 
points in both treatment groups would show statistically significant improvement compared to 
baseline if the average age of stem cell donors for the auto-hMSC group was reduced to match 
that of the allo-hMSC group, or that the study cannot be considered reliable due potential 
confounding variables resulting from this difference.  
 
Level of Evidence: 1B  
 
DISCUSSION 
Nonischemic dilated cardiomyopathy is a progressive and deadly disorder with a 
significant global impact and only one curative treatment option at this time: a total heart 
transplant. Stem cell therapy in the setting of NIDCM is hypothesized to provide another 
curative option for this disorder as evidence shows potential for this therapy to regenerate 
damaged heart tissue, in turn increasing functional capacity and, therefore, quality of life.  
End point measurements of cardiac improvement after stem cell therapy being evaluated 
in this paper include the 6-minute walk test (6MWT) and left ventricular ejection fraction (LVEF). 
The 6MWT is frequently used to determine functional capacity in patients with heart failure. In 
this test, the patient is asked to walk, self-paced, back and forth between 2 marked points on a 
flat surface for 6 minutes. Rests are allowed and the total number of meters walked at the 6-
minute mark is calculated. A review paper has shown that the 6MWT is a reliable and valid test 
for estimating functional capacity in patients with heart failure, as the test was between 83% and 
91% accurate in predicting peak oxygen uptake (VO2) when total distance walked was less than 
490 meters, with VO2 being universally accepted as a measurement for functional capacity.14 
LVEF is defined as the percent volume that is ejected during systole from the left ventricle. 
LVEF has been the primary parameter used in the diagnosis, management, and both symptom 
severity and outcome predictor in patients with heart failure.15 This review focuses on recent 
evidence that stem cell therapy causes short term improvement in the 6MWT and LVEF in the 
setting of nonischemic dilated cardiomyopathy.  
 Overview of details and results of the three studies evaluated in this paper are 
summarized in Table 5. Sample sizes of all three studies are too small to draw definitive 
conclusions from results and the small sample sizes combined with the stringent inclusion and 
exclusion criteria lead to restricted demographics in the studies. All three studies show 
significant short-term improvement in 6MWT results and two of the three studies show 




the theory that stem cell therapy may stimulate regeneration of healthy heart tissue. This 
suggests that larger scale future studies should be done to validate the results from these three 
trials.  
While all three studies include patients with nonischemic dilated cardiomyopathy and 
evaluate safety and efficacy endpoints including LVEF and 6MWT, the specific type of stem cell, 
delivery method, and follow-up time points vary greatly between the three studies. Butler et al. 
was unique in that it is the first published experiment with intravenously-administered stem cells 
in patients with any type of chronic cardiomyopathy. Vrtovec et al. is the first clinical study 
investigating the effects of repetitive transplantation of CD34+ cells in patients with NIDCM, 
although repetitive treatment administration was not associated with improved clinical response 
except for a noticeable increase of myocardial viability in certain subsets of patients. Hare et al. 
is the first study comparing allogeneic and autologous human mesenchymal stem cells in the 
treatment of NIDCM.  
 Results regarding safety and efficacy of treatment in all three studies, in spite of 
differences in stem cell type and delivery method, showed no life-threatening adverse effects or 
concerns for patient safety. We assume that there were minor adverse side effects (i.e. pain 
from bone marrow harvesting for auto-stem cell donors), but these studies only focused on 
serious, short-term, and life-threatening adverse outcomes. This focus is appropriate for early 
phase human trials, but future studies will be needed to further evaluate life-threatening adverse 
events as well as other safety endpoints. Of note, it will be difficult to interpret data regarding 
any adverse effects that arise after a significant amount of time has passed post-stem cell 
treatment of NIDCM, since the morbidity and mortality of NIDCM is so high without treatment.  
 An important aspect of this experimental therapy to consider is the cost of treatment. 
The current accepted bridging therapy to heart transplantation for NIDCM is the use of left 
ventricular assist devices (LVAD), which cost several hundred thousand dollars to place and, 
more often than not, require the patient to remain hospitalized while the LVAD is in place. Many 
insurances do cover at least a significant portion of the cost of the LVAD when it is needed and 
Medicare is currently in the progress of including LVAD costs in their coverage; however, the 
device itself and the hospitalization it requires results in significant medical costs to both the 
patient and insurance companies. Stem cell therapy for NIDCM is still in experimental stages 
and the total cost of therapy is not known at this time, but it is estimated to be extremely 
expensive due to the complexity and novelty of the procedures required to obtain, expand, and 
administer the stem cells colonies. The LVAD has been proven to be an effective bridging 




appear to increase quality of life during brief short-term periods after treatment. Additionally, 
repeat stem cell treatments only seem to improve longer term outcomes for a very small subset 
of patients. At this time, it will be necessary to find a way to prolong the effects of stem cell 
therapy in the setting of NIDCM in order for it to be considered an effective bridging therapy 
option for heart transplant candidates. Stem cell therapy could, however, be effective in patients 
with advanced NIDCM who are not candidates for heart transplantation. This treatment could 
help improve their quality of life, and, hopefully, as this technology improves and advances, the 
stem cell therapy could regenerate healthy myocardium, potentially reversing the effects of the 
disease and further improving quality of life, as well as prolonging life.  
 The only potential bias noted in any study evaluated in this paper was involvement of 
several authors from Study #1 (Butler et al.) with CardioCell, which is a global biotechnology 
company that explores therapeutic applications of unique patented ischemia-tolerant 
mesenchymal stem cells (itMSCs) manufactured under cGMP conditions. CardioCell has an 
exclusive worldwide license from Stemedica Cell Technologies Inc. for the exploration of 
therapeutic cardiovascular indications, including acute myocardial Infarction (AMI), chronic heart 
failure (CHF), and peripheral artery disease (PAD). 
 






Stem cell therapy is shown to be safe, well-tolerated, and effective in improving 
functional capacity, quality of life, and short-term event survival in patients with nonischemic 
cardiomyopathy. All three studies displayed short-term improvements in LVEF and/or 6MWT, 
with a small sample size. No major adverse events were attributed to the interventions. Further 
randomized controlled trials are warranted in order to validate long-term results in a larger 
population before a clinical recommendation can be given; however, because of these positive 
results and potential therapeutic effect, large institutions will likely be willing to fund future 
studies. Further research should be done to explore the hypothesis that the positive findings are 
a result of immunomodulatory factors stimulated by the act of transplantation, rather than the 
stem cells, exclusively. If this is the case, a more cost-effective synthetic injection could likely be 
created to stimulate the same response, limiting the need to harvest human stem cells. In 
conclusion, stem cell therapy is a promising alternative therapeutic option for patients with 
nonischemic cardiomyopathy.   
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